-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As an emerging drug, peptide drugs are currently approved for marketing in the world far fewer than small-molecule drugs, but they have increasingly become one of the hotspots of global new drug research and development, such as Pfizer, Merck, Roche, Eli Lilly, Novartis, and Cypress.
According to statistics from Ferring Pharmaceutical Research Institute in 2016, the top 10 peptide pharmaceutical companies in the world include Teva, NovoNordisk, Novartis, AstraZeneca, and EliLilly.
Global peptide drug market size
According to QYResearch statistics: the global peptide drug market was approximately US$15.
Global peptide drug market size statistics
Source: Lonza, QYResearch Shengnuo Biological Prospectus
Global peptide drug market distribution
According to statistics from Reseach Nester, in terms of global market regional distribution, the United States is the most important market for peptide drugs, accounting for 74%, followed by Europe, accounting for 15%
Data source: Reseach Nester
8 major varieties of peptide drugs
At present, dozens of peptide drugs in the global market have shown great clinical application value and wide application prospects.
The total sales of the top 8 varieties exceed 18 billion U.
Novo Nordisk's two blockbuster products, Semaglutide and Liraglutide, have combined sales of approximately US$7.
Data source: financial report
According to data from Evaluatepharma, a medical research organization, the market size of orphan diseases/rare diseases, tumors, and diabetes in peptide drugs are all over 3 billion US dollars, while the remaining four fields, digestive tract, orthopedics, immunity, and cardiovascular and cerebrovascular are relatively small.
Data source: financial report
In the next two years, the patents of two peptide drugs goserelin and linaclotide will expire
Data source: Prospectus of Shengnuo Biotechnology of the State Drug Administration
to sum up
There are still many favorable factors for the development of the global peptide drug market in the future, including the increase in drug delivery convenience and cost reduction brought about by technological progress, and the increase in R&D investment driven by higher approval rates
